Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival

References

• Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71:462–475.
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro JA, Martin MG, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomised phase III study. J Urouxy. 1995;153:964–973.
   PubMed Web of Science ®Google Scholar
• International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-Urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbla and CUE de TO (CUETO) group. Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999;354:533–534.
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro JA, Martinez-Pineiro L. The role of neoadjuvant chemotherapy for invasive bladder cancer. Br J Urol. 1998;82:33–42.
   PubMedGoogle Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866.
   PubMed Web of Science ®Google Scholar
• Leveridge MJ, Siemens DR, Mackillop WJ, et al. Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study. Urology. 2015;85:791–798.
   PubMed Web of Science ®Google Scholar
• Rintala E, Hannisdahl E, Fosså SD, et al. Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand J Urol Nephrol. 1993;27:355–362.
   PubMed Web of Science ®Google Scholar
• Collaboration ABC (ABC) M-A. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48:202–206.
   PubMed Web of Science ®Google Scholar
• Roche N, Reddel H, Martin R, et al. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Annals Ats. 2014;11:S99–S104.
   Google Scholar
• Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110:551–555.
   PubMed Web of Science ®Google Scholar
• Haggstrom C, Liedberg F, Hagberg O, et al. Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Database Sweden (BladderBaSe). BMJ Open. 2017;7:e016606.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659–667.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Almqvist C, Bonamy AKE, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125–136.
   PubMed Web of Science ®Google Scholar
• Brooke HL, Talbäck M, Hörnblad J, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32:765–773.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Berglund A, Garmo H, Tishelman C, et al. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011;185:833–839.
   PubMed Web of Science ®Google Scholar
• Sweden S. Longitudinal Integration Database for Health Insurance and Labor Market Studies. 2010.
   Google Scholar
• Stenzl A, Cowan NC, Santis MD, et al. Guidelines on bladder cancer: muscle-invasive and metastatic. European Association of Urology. 2008.
   Google Scholar
• Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two nordic studies. Eur Urol. 2004;45:297–303.
   PubMed Web of Science ®Google Scholar
• Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171–2177.
   PubMed Web of Science ®Google Scholar
• Sengeløv L, Von Der Maase H, Lundbeck F, et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol (Madr). 2002;41:447–456.
   PubMed Web of Science ®Google Scholar
• Collaboration ABC (ABC) M-A. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927–1934.
   PubMed Web of Science ®Google Scholar
• Hernán MA, Sauer BC, Hernández-Díaz S, et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses HHS Public Access. J Clin Epidemiol. 2016;79:70–75.
   PubMed Web of Science ®Google Scholar
• Singal AG, Higgins PDR, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5:e45.
   PubMed Web of Science ®Google Scholar
• Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495.
   Web of Science ®Google Scholar
• Littnerova S, Jarkovsky J, Parenica J, et al. Why to use propensity score in observational studies? Case study based on data from the Czech clinical database AHEAD 2006–09. Cor Vasa. 2013;55:e383–e390.
   Google Scholar
• D’Agostino RB. Propensity scores in cardiovascular research. Circulation. 2007;115:2340–2343.
   PubMed Web of Science ®Google Scholar